白雲山(600332.SH):擬以9.99億元認購廣藥基金份額
格隆匯3月18日丨白雲山(600332.SH)公佈,公司擬作為有限合夥人以自有資金9.99億元人民幣認購廣州廣藥基金股權投資合夥企業(有限合夥)(擬定名,具體以企業登記機構核准的名稱為準,“廣藥基金”或“本基金”)份額,佔廣藥基金認繳出資總額的99.90%。
廣藥基金的管理人為廣州廣藥資本私募基金管理有限公司(“廣藥資本”),廣藥資本是公司控股股東廣州醫藥集團有限公司(“廣藥集團”)持股80%的控股子公司。廣藥資本作為執行事務合夥人、基金管理人和普通合夥人認繳100萬元基金份額。公司副董事長程寧擔任廣藥資本的董事長。因此,公司本次認購廣藥基金份額構成關聯交易。
基金投資方向包括子基金投資、股權投資、與股權相關的投資以及其他符合適用法律規定的投資。基金及基金投資的子基金圍繞公司戰略規劃,聚焦生物醫藥健康領域的股權投資,主要包括:1、公司內部優質資源整合及資本運作;2、公司大南藥、大健康、大商業、大醫療四大業務板塊對外投資、併購;3、生物醫藥、醫療器械、智慧醫療等醫藥戰略新興產業。
此次投資有利於公司發現和培育符合公司主業發展方向、具有一定市場競爭力的項目標的,在豐富公司產業結構的同時,為公司未來可持續發展提供項目儲備。同時有利於公司提升資本運作能力及加快對外投資步伐,將促進公司加速在生物醫藥健康產業領域的轉型升級、實現快速發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.